Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 1,034.50
-2.40 (-0.23%)
Sep 16, 2025, 3:30 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 65.74B INR in the quarter ending June 30, 2025, with 5.90% growth. This brings the company's revenue in the last twelve months to 236.08B, up 14.52% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
236.08B
Revenue Growth
+14.52%
P/S Ratio
4.42
Revenue / Employee
8.46M
Employees
27,917
Market Cap
1,043.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
| Aurobindo Pharma | 320.25B |
Zydus Lifesciences News
- 21 hours ago - Zydus Lifesciences’ ZyVet launches first veterinary-approved generic of Furosemide tablets - Business Upturn
- 21 hours ago - Zydus Lifesciences’ ZyVet launches first FDA-approved generic treatment for canine urinary incontinence - Business Upturn
- 5 days ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga
- 11 days ago - Zydus Lifesciences shares jump over 2% as subsidiary enters into licensing and supply agreement with Synthon BV - Business Upturn
- 11 days ago - Top stocks to watch today, September 5: HDFC Life, HCLTech, Zydus Lifesciences, Bharat Forge and more - Business Upturn
- 11 days ago - Stocks to watch today, Sept 5: Sterlite Tech, JB Chemicals, Bharat Forge, Zydus Lifesciences, Varun Beverages in focus - Business Upturn
- 11 days ago - ICMR issues licences to industry partners for 9 breakthrough techs - The Times of India
- 12 days ago - Zydus enters exclusive licensing deal with Synthon for Ozanimod capsules in US market - Business Upturn